ImmunoGen (IMGN -0.5%) says that Amgen (AMGN -0.2%) has licensed the exclusive right to use the company's maytansinoid TAP technology to develop anticancer therapeutics to a third target, which is undisclosed. For each license, IMGN receives a $1M upfront payment and is entitled to receive milestone payments potentially totaling $34M plus royalties on the sales of any resulting products. AMGN is responsible for the development, manufacturing and marketing of any products resulting from the license.
ImmunoGen (IMGN -0.5%) says that Amgen (AMGN -0.2%) has licensed the exclusive right to use the...
From other sites
at CNBC.com (Dec 19, 2014)
at CNBC.com (Dec 2, 2014)
at CNBC.com (Sep 8, 2014)
at CNBC.com (Aug 14, 2014)
at CNBC.com (Jun 25, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs